We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Neurobo Pharmaceuticals Inc (NRBO) USD0.001

Sell:$1.45 Buy:$1.49 Change: $0.03 (1.97%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Sell:$1.45
Buy:$1.49
Change: $0.03 (1.97%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Sell:$1.45
Buy:$1.49
Change: $0.03 (1.97%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). It also focused on developing capsule formulation of niclosamide for coronavirus indications.

Contact details

Address:
200 BERKELEY ST., FL 19
BOSTON
02116
United States
Telephone:
+1 (857) 7029600
Website:
https://www.neurobopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NRBO
ISIN:
US64132R1077
Market cap:
$42.82 million
Shares in issue:
26.59 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Douglas Swirsky
    Chairman of the Board
  • Gil Price
    President, Chief Executive Officer
  • Akash Bakshi
    Chief Operating Officer, Senior Vice President
  • Andrew Bartynski
    Senior Vice President
  • Nadja Mannowetz
    Senior Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.